Evidence map›Paper›PMID 31215017›Full record

ArticleJournal of racial and ethnic health disparities2019

Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database.

Mark B Ulanja, Mohit Rishi, Bryce D Beutler, Kenneth G Konam, Santhosh Ambika, Tomas Hinojosa, Francis T Djankpa, Wei Yang, Nageshwara Gullapalli

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of racial and ethnic health disparities, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mark B UlanjaDepartment of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA. mulanja@unr.edu.ORCID 0000-0001-5966-3966
Mohit RishiDepartment of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA.
Bryce D BeutlerDepartment of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA.
Kenneth G KonamCollege of Arts and Sciences, Vanderbilt University, Kirkland Hall, 2201 West End Ave., Nashville, TN, 37235, USA.
Santhosh AmbikaDepartment of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA.
Tomas HinojosaVA Sierra Nevada Health Care System, 975 Kirman Ave., Reno, NV, 89502, USA.
Francis T DjankpaUniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA.
Wei YangCenter for Surveys, Evaluation and Statistics, School of Community Health Sciences, University of Nevada, Reno, 1664 N. Virginia St., Reno, NV, 89557, USA.
Nageshwara GullapalliDepartment of Internal Medicine, University of Nevada, Reno School of Medicine, 1155 Mill St., Reno, NV, 89502, USA.
University of Nevada, Reno · USUniformed Services University of the Health Sciences · USVanderbilt University · USVA Sierra Nevada Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrointestinal tumors (GISTs) represent the most common mesenchymal tumors of the gastrointestinal tract. There has been limited data on GIST incidence and survival disparities between ethnic groups.

aimsAssess disparities in incidence and survival among race in the USA in the era of available GIST histologic codes and treatment.

methodsWe queried Surveillance, Epidemiology, and End Results (SEER) database for GIST from 2002 to 2015, with diagnostic code 8936.

resultsOf the 7204 patients identified, 4928 (68.4%) were White, 1308 (18.2%) African American (AA), and 968 (13.4%) were classified as "Other" (American Indian/Alaskan Native, Asian/Pacific Islander). The overall incidence rate (IR) was 0.75 per 100,000. IR was highest among AA at 1.37/100,000, but 0.65/100,000 for Whites, 1.10/100,000 for Asians/Pacific Islanders, and 0.28/100,000 for American Indians/Alaskan Natives. The GIST incidence was twice as high for AA as for Whites (rate ratio [RR]: 2.12; 95% CI: 1.98-2.26; p < 0.001). There was higher proportion of Whites than AA, who underwent surgical extirpation. Median overall survival (OS) and GIST specific survival (GSS) were not reached for all race, which indicates more than half of the patients were still alive at end of follow-up period. In multivariate Cox model, belonging to "Other" had better OS (adjusted hazard ratio [aHR]; 0.73, 95% CI: 0.55-0.95, P = 0.021) for GIST, but no difference in prognosis and OS for AA and White [(aHR for whites; 0.84, 95% CI: 0.69-1.02, P = 0.071), AA = reference]. There was no difference in GSS among races.

conclusionsSignificant racial disparity in incidence and overall survival for GIST exists, and efforts should be made to bridge this gap and improve outcomes for all races. The overall incidence rate for GIST was noted to be 7.5 per 1 million, and IR of GIST was twice as high for African Americans as compared to Whites. The "Other" racial group (American Indians/Alaskan Natives, Asians, and Pacific Islanders) had superior OS as compared to African Americans and Whites.

Indexed as

Health Status DisparitiesAdultAgedDatabases, FactualFemaleGastrointestinal Stromal TumorsHumansIncidenceMaleMiddle AgedRacial GroupsRetrospective StudiesSEER ProgramSurvival AnalysisUnited StatesGastrointestinal stromal tumorsIncidence of GISTIncidence rateMedian survivalRace disparitySurveillance epidemiology and end results

Identifiers

PMID31215017
OpenAlexW2950903008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.